The DETOURS Trial: De-escalating Empiric Treatment: Opting Out of Rx for Selected Patients With Suspected Sepsis - Opt-Out Protocol Trial

Status:	Recruiting
Conditions:	Hospital
Therapuetic Areas:	Other
Healthy:	No
Age Range:	18 - Any
Updated:	3/16/2019
Start Date:	September 12, 2018
End Date:	March 30, 2020
Contact:	Bobby Warren, MPS
Email:	bobby.warren@duke.edu
Phone:	9196817957

The objective of this study is to implement an opt-out protocol to guide appropriate
de-escalation of antibiotics in qualifying patients. The protocol, determined over the course
a year with the help of a large, well-rounded expert panel, will be used by pharmacists to
recommend de-escalation of antibiotics to hospital providers. Providers can then decide
whether or not to follow the recommendation in determining the best treatment pathway for his
or her patient.

Inclusion Criteria:

- Blood culture preliminary results that indicate no growth as of 48-96 hours.
(Exception: Patients with a single positive blood culture for coagulase negative
Staphylococcus and no central line in place will also be included).

- Still on broad spectrum antibiotic therapy after 48-96 hours.

Exclusion Criteria:

- Adult patients who are located in ICU wards.

We found this trial at

sites

Harvard/Brigham and Women's Hospital

Boston, Massachusetts 02138

Principal Investigator: Michael Klompas, MD

Phone: 617-867-4991

from

Boston, MA